Opiate Substitution Treatment: An Overview Ron Jackson, M.S.W. Evergreen Treatment Services Seattle, WA.

Slides:



Advertisements
Similar presentations
13 Principles of Effective Addictions Treatment
Advertisements

Models of Evaluation of Addiction Treatment Outcome Post-Treatment vs. During Treatment Evaluation of Effectiveness.
1 CHANGES IN SEXUAL INTEREST AND PERFORMANCE FOLLOWING OPIATE DETOXIFICATION AND ORAL NTX TREATMENT A PROSPECTIVE STUDY Emmanuel Koukidis, MSc, BTEC in.
Nora D. Volkow, M.D. Director National Institute on Drug Abuse Nora D. Volkow, M.D. Director National Institute on Drug Abuse What Do We Know? Drug Abuse.
The intranasal heroin epidemic among Latino adolescents in Texas: they're calling it "cheese." Background: Since 2005, Dallas County has experienced a.
Nora D. Volkow, M.D. Director National Institute on Drug Abuse Nora D. Volkow, M.D. Director National Institute on Drug Abuse RESEARCH and TREATMENT Provide.
Translating Research to Practice in Treating Substance Use Disorders Richard Rawson, Ph. D. UCLA Drug Abuse Research Center Matrix Institute on Addictions.
Sublingual Buprenorphine and Pain
Copyright Alcohol Medical Scholars Program 1 Opioid Agonist Treatment: “Trading one substance for another?” Joseph Sakai, M.D.
John R. Kasich, Governor Tracy J. Plouck, Director Andrea Boxill, Deputy Director Andrea Boxill, Deputy Director Governor’s Cabinet Opiate Action Team.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2008.
Alcoholism and Substance Abuse. Focus Alcoholism.
Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.
Understanding Drug Abuse and Addiction: What Science Says Developed by the National Institute on Drug Abuse (NIDA) National Institutes of Health Bethesda,
Developments in Community - Based Drug Treatments Lesley Peters
Diagnosis And Treatment Of Prescription Opioid Dependence Steven W. Clay, D.O. Associate Professor, Department of Family Medicine Ohio University College.
Psychopharmacotherapy in Correctional Institutions Robert P. Schwartz, M.D. Friends Research Institute Supported by NIDA R01 DA (PI: Kinlock)
HIV Risk Reduction With Buprenorphine- Naloxone or Methadone: Findings From A Randomized Trial G. Woody, D. Bruce, P. T. Korthuis, S. Chhatre, M. Hillhouse,
SUBSTANCE USE DISORDERS GENERAL METHODS OF TREATMENT Inpatient Detoxification and Rehabilitation Outpatient Individual, Couple, or Family Counseling Self-help.
The Value of Ongoing Evaluation in Adopting Buprenorphine-Naloxone Short-term Taper Gregory S. Brigham, Ph.D. Maryhaven, Columbus, Ohio NIDA CTN Ohio Valley.
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module III – Buprenorphine 101.
Medication Assisted Therapy for Opioid Addiction: Methadone and Buprenorphine Andrew J. Saxon, M.D. Veterans Affairs Puget Sound Health Care System and.
Responding to Drug Abuse and Addiction: What Science Says Developed by the National Institute on Drug Abuse (NIDA) National Institutes of Health Bethesda,
Re-Considering Addiction Treatment How Can Treatment be More Accountable and Effective? Lessons from Mainstream Healthcare.
C:\laam\lamAPA.ppt 8/04/98 Heroin Addiction Treatment: A Comparison of Methadone and LAAM M. Douglas Anglin, Ph.D. Douglas Longshore, Ph.D. Jeffrey J.
Scientific Evidence Module 2. The evidence of effectiveness Most research is on methadone, much less on other medications Has proven effective for the.
Results of the Vivitrol Pilot in Los Angeles County Presented by: Desiree A. Crevecoeur-MacPhail, Ph.D. Research Psychologist, UCLA ISAP.
OPIOID SUBSTITUTION THERAPY
Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006
Addiction Treatment as HIV Prevention Charles P. O’Brien, MD, PhD David Metzger, PhD George E. Woody, MD University of Pennsylvania Treatment Research.
Buprenorphine Therapy in Primary Care: One Prescriber’s Experience Pittsburgh, PA August 24, 2005 Melinda Campopiano, M.D. Baron Edmond de Rothschild Chemical.
Medical issues about Methadone : What the counselor needs to know
PRINCIPLES OF DRUG ADDICTION TREATMENT Dr. K. S. NJUGUNA.
Program Components and Key Concepts for Drug Court Services Matrix Institute on Addictions Rancho Cucamonga, California – 2001.
Understanding Drug Abuse and Addiction: What Science Says Developed by the National Institute on Drug Abuse (NIDA) National Institutes of Health Bethesda,
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
Buprenorphine and the NIDA CTN: Research to Practice Walter Ling & Richard Rawson ISAP/UCLA XIII World Congress of Psychiatry September 14, 2005 Cairo,
Module 1 General introduction to substitution treatment.
Clinical Management of Substance Misuse Dave Marteau Prison Health
The Counseling Center, Inc. Devoted to the prevention and treatment of alcoholism and other drug addictions. We promote opportunities for individuals and.
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
BUPRENORPHINE TREATMENT: A Training For Addiction Professionals BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals Module.
Opioid Pharmacotherapy: An Introduction Walter Ling, MD Integrated Substance Abuse Programs (ISAP) UCLA International Symposium on Drug Abuse and Addictive.
NYSDOH/AI The Role of Methadone in HIV Prevention And Treatment Sharon Stancliff, MD Medical Consultant AIDS Institute New York State Department of Health.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
Principles of Effective Drug Addiction Treatment Health 10 The Truth About Drugs Ms. Meade.
BEHAVIORAL FAMILY COUNSELING AND NALTREXONE FOR MALE OPIOID-DEPENDENT PATIENTS William Fals-Stewart, Ph.D. Research Institute on Addictions.
Understanding Drug Abuse and Addiction: What Science Says Developed by the National Institute on Drug Abuse (NIDA) National Institutes of Health Bethesda,
Opioid Treatment Basics for Counselors Thomas E. Freese, PhD Pacific Southwest Addiction Technology Transfer Center UCLA Integrated Substance Abuse Programs.
Buprenorphine {Suboxone®, Subutex®}
What the National Institute on Drug Abuse’s Clinical Trials Network Can Do for You? Major Findings from Medication Trials and Implications for Community-Based.
Buprenorphine Joseph Merrill M.D., M.P.H. University of Washington Harborview Medical Center.
FAMILY RECOVERY NETWORK EVENT: What is Substance Abuse Treatment? Patrick Seche, MS, CASAC Strong Recovery Addiction Psychiatry Division Department of.
Challenges and Opportunities for the Use of Medications to Treat Chronic Opioid Addiction in the United States Mark W. Parrino, M.P.A. Thursday, April.
Medication Assisted Treatment for Opioid Use Disorders
Benjamin Nordstrom MD, PhD VP, Medical Director for Program Development Phoenix House Foundation.
Suboxone and Opioid Trends Joseph Merrill M.D., M.P.H. University of Washington June 16, 2009.
Medications for the Treatment of Opioid Addiction Robert P. Schwartz, M.D. Friends Research Institute.
Medication Assisted Treatment Daniel T. Brown, D.O. Medical Director, Meridian HealthCare.
What does pharmacology have to do with treatment of heroin addiction?
Drugs and Neuron Communication
SBIRT..What should I know?
Medication-Assisted Treatment 101: Breaking the Stigma
Pain Management: Patients Maintained on Buprenorphine
RIDOC BASED MAT FOR OPIATE USE DISORDERS
Michael C. White, MCJ
The relationship between incarceration and opioid addiction treatment
Medications used in Treatment of Alcohol and Drug Use Disorders
Medically assisted treatment
Presentation transcript:

Opiate Substitution Treatment: An Overview Ron Jackson, M.S.W. Evergreen Treatment Services Seattle, WA

HEROIN There were 32 heroin-related deaths in the first half of These represent 37% of all drug deaths. Of the heroin-related drug deaths: 27 (84.4%) had one or more other drugs in their system at the time of death. 72% of decedents were male; 94% Caucasian; 3% African-American; 3% Hispanic.

HEROIN

The rate of ED heroin mentions has remained stable since Treatment admissions have increased 33% since ADAM data showed male arrestees tested positive for opiates at the rate of 9.9% in 2000 and 11.7% in the first quarter of Heroin prices seem stable.

Trends in ED mentions – ( rate per 100,000 population)

ADDICTION “Addiction is a brain disease shaped by behavioral and social context.” Dr. Alan Leshner, Director National Institute on Drug Abuse “It’s like I’ve got a shotgun in my mouth, my finger’s on the trigger and I like the taste of gun metal.” Robert Downey, Jr. Actor

Addiction as a Brain Disease lProlonged drug use Pervasive changes in brain function that 4Persist after drug use stops 4Can be demonstrated at many levels VMolecular VCellular VStructural VFunctional

Drug Dependence: A Chronic Medical Illness Genetic Heritability – twin studies Hypertension – 25-50% Diabetes – Type 1: 30-55%; Type 2: 80% Asthma – 36-70% Nicotine – 61% (both sexes) Alcohol – 55% (males) Marijuana – 52% (females) Heroin –34% (males) Voluntary Choice – shaped by personality and environment Pathophysiology – neurochemical adaptations Treatment Response Medications – effectiveness and compliance Behavioral interventions McLellan, A.T., et.al., Drug Dependence, a Chronic Medical Illness Journal of the American Medical Association 284: , 2000.

581 Male Heroin Addicts Followed for 33 Years Hser et al., 2001

Adapted from: JAMA, Dec. 9, 1998, 280 (22), NIH Consensus Panel on Effective Medical Treatment of Opiate Addiction 12 member multi-disciplinary panel, Nov heard testimony from 25 experts reviewed 941 research reports published over the period Jan Sept “Of the various treatments available, MMT, combined with attention to medical, psychiatric, and socioeconomic issues, as well as drug counseling, has the highest probability of being effective.”

Comparing Methadone and Heroin

LAAM: Levo-Alpha Acetylmethadol A Long-Acting Opiate Agonist Pharmacological Action Metabolites more active than parent drug Advantages One dose lasts 48 to 72 hours Fewer trips to the clinic Better heroin blockage Disadvantage Cardiac complications

Methadone Dose: How much is enough? Leavitt, SB, et.al., When “Enough” is Not Enough. Mt Sinai Journal of Medicine 2000: 67(5&6):

Admission Criteria Adult y.o. needs parental/guardian permission Currently physiologically dependent on an opiate Exceptions for incarcerated persons and for those who had previously successfully completed treatment Current dependence on other drugs doesn’t disqualify If in treatment more than 180 days, patient needs documentation of at least one year’s history of opiate dependence.

Treatment Requirements Attendance for observed dosing 6 days a week for the first 90 days (methadone); 3 days a week indefinitely (LAAM) Take-home doses permitted after 90 days but only to those patients meeting a number of criteria At least once per month observed urinalysis Some clinics have contingencies; some don’t Some agencies administer alcohol breath tests; some don’t Primary counselor assigned; weekly counseling for at least the first 90 days zAdditional education, i.e., HIV/HCV, family planning

Opiate Substitution Treatment Goals Primary Goals: Reduction in of illicit opiate use. Retention in treatment for 1-2 years or more. Secondary Goals: Reduction in cocaine, alcohol, and other drug abuse. Reduction in transmission of infectious diseases by unsterile injection equipment. Reduction in criminal activity. Increase in pro-social activity — employment, education, child care, etc.

Methadone Maintenance vs. 180 Day Detoxification 12 month study of 179 opioid dependent patients randomly assigned to: lMethadone Maintenance 3mean dose=85.3mg 3for 14 months l180 Day Methadone Detoxification 3mean dose=86.3 mg prior to taper at 120 days 3followed by psychosocial Tx for 8 months K.L. Sees et al., JAMA 2000

Adapted from: Ball & Ross, Reduction of Heroin Use By Length of Stay in Methadone Treatment Pre- treatment Admission: < 6 months stay Average Stay: 6 to 54 months Long-term: > 54 months

Adapted from V. Dole (1989) JAMA, 282, p Frequency of Heroin Use & Methadone Dose Level

Drug Use & Length of Time in Methadone Treatment

Percentage of Patients with + U/A January – December, 2001 Van service

Adapted from: Ball & Ross, The Effects of Methadone Treatment on Crime Days 70.8% Decline in Crime Days 94% n= 617

Changes in Illegal Activity Preliminary findings, DASA, Washington State Outcomes Project, 2002

Changes in Illegal Activity Preliminary findings, DASA, Washington State Outcomes Project, 2002

Comparing Retention Methadone (6 mos.) vs. “Drug-free” (3 mos.) Preliminary findings, DASA, Washington State Outcomes Project, 2002

Comparing 6 month Outcomes Methadone vs. “Drug-free” Preliminary findings, DASA, Washington State Outcomes Project, 2002

Determining the Value of Opiate Substitution Treatment Washington State DASA, Management Report, December, n=726 2 n=363

from D. Calsyn, NIDA Grant # R18DA06104 Initial & 18 Month Self-Report Data From 78 Methadone Patients

Comparing Retention Methadone (6 mos.) vs. “Drug-free” (3 mos.) Preliminary findings, DASA, Washington State Outcomes Project, 2001

Comparing 6 month Outcomes Methadone vs. “Drug-free” Preliminary findings, DASA, Washington State Outcomes Project, 2001

Methadone and Criminal Justice

from D. A. Calsyn, NIDA Grant # RA18 DA Women in Methadone Treatment: Reduction in Prostitution % of women admitting to prostitution in previous 6 months 28% 0% 13%

Adapted from: Marsch, L.A. Addiction 93(4), , Efficacy of Methadone Maintenance: A meta-analysis Estimation of Results with Intervention* * based on the effect sizes observed in meta-analysis (# of studies)

Adapted from: Ball & Ross, Characteristics of Successful Methadone Treatment Programs Adequate Dosing Policies  Average Dose Between 60 & 120mg. Comprehensive Services Well-trained & Stable Staff Individualized Treatment Coordinated Services  Medical, Counseling & Administration

Swedish Methadone Study Before Experimental Group (Methadone) Control Group (No Methadone) Gunne & Gronbladh, 1981

Swedish Methadone Study After 2 Years Experimental Group (Methadone) Control Group (No Methadone) Gunne & Gronbladh, 1981 d ab c dd a Sepsis b Sepsis and Endocarditis c Leg Amputation d In Prison

Adapted from: Ball & Ross, Return to I.V. Drug Use Following Premature Termination of Treatment %IV USERS%IV USERS Months Since Dropout

BUPRENORPHINE Partial agonist at Mu-opiate receptor  less subjective “high” Slowly dissociates from those receptors  slow onset & offset Once-a-day dosing Sublingual administration  compounded with naloxone (BUP/NX) which will precipitate abrupt withdrawal if injected

Opiate Antagonists Naloxone (NARCAN ® ) 3treatment for acute opiate overdose Naltrexone (ReVia ® ) 3detoxification from physical dependence on opiates 3opiate “blocker” - aid to maintenance of abstinence from opiates  Clonidine (Catapres ® ) - not an antagonist - suppresses withdrawal symptoms